

FILE 'CAPLUS' ENTERED AT 13:05:51 ON 01 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:05:51 ON 01 SEP 2006

FILE 'BIOSIS' ENTERED AT 13:05:51 ON 01 SEP 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:05:51 ON 01 SEP 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s polyhydroxy-aldonic(w)lactone or gluconolactone
L1 2180 POLYHYDROXY-ALDONIC(W) LACTONE OR GLUCONOLACTONE

=> s rosacea or dilated(w)blood(w)vessels or telangiectasia or erythema or papule?
or pustule?
L2 107435 ROSACEA OR DILATED(W) BLOOD(W) VESSELS OR TELANGIECTASIA OR
ERYTHEMA OR PAPULE? OR PUSTULE?

=> s anti-acne(w)agent or anti-acne(w)medic? or benzoyl(w)peroxide
L3 16903 ANTI-ACNE(W) AGENT OR ANTI-ACNE(W) MEDIC? OR BENZOYL(W) PEROXIDE

=> s l1 and l2 and l3
L4 4 L1 AND L2 AND L3

=> d ti au abs py so

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Bioavailability and improved delivery of alkaline pharmaceutical drugs
IN Yu, Ruey J.; Van Scott, Eugene J.
AB Embodiments of the invention relate to a composition, a process of making the
composition, and to the use of the composition The compns. include a mol.
complex
formed between an alkaline pharmaceutical drug and at least one selected from
a hydroxy acid, a polyhydroxy acid, a related acid, a lactone, or
combinations thereof. The compns. provide improved bioavailability and
improved delivery of the drug into the cutaneous tissues. For example,
diphenhydramine hydrochloride 29 g (0.1 mol) was dissolved in water and 5
N sodium hydroxide generating diphenhydramine free base.
Gluconolactone 18 g (0.1 mol) was added to form a mol. complex of
0.1 mol diphenhydramine free base with 0.1 mol gluconic acid/
gluconolactone. The solution thus obtained was used for various
forms of topical formulations including oil-in-water creams, lotions, gels
and solns.
PY 2005
2004
2006
SO U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 792,273.
CODEN: USXXCO

=> d ti au abs py so 2-4

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Method and preparation for reducing irritation and/or inflammatory
reaction in human skin
IN Dinardo, Joseph C.; Lewis, Joseph A., II; Neudecker, Birgit; Diedrich,
Falko; Wieland, Eberhard
AB A method for reducing an occurrence of irritation and/or inflammatory
reaction in human skin includes applying a topical preparation to the skin.
The topical preparation includes an agent effective to reduce an occurrence of

irritation and/or inflammatory reaction in human skin. The agent includes idebenone or a derivative of idebenone. Idebenone significantly reduced the irritation potential produced by prescription retinoid tested when used as a pretreatment for 2 wk.

PY 2005
2006
2005
2006

SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Topical treatment of dermatological disorders associated with reactive or dilated blood vessels

IN Yu, Ruey J.; Van Scott, Eugene J.

AB The invention provides a method of topically treating a dermatol. disorder. The method includes topically applying a therapeutically effective amount of a cosmetic or dermatol. composition to an affected area of the skin. The composition includes at least one compound that is (i) a polyhydroxy-alldonic acid, (ii) a polyhydroxy-alldonic lactone, (iii) a polyhydroxy-allduronic acid, (iv) a polyhydroxy-allduronic lactone, (v) a polyhydroxy-alldaric acid; (vi) a polyhydroxy-alldaric lactone, and (vii) an organic acid lactone having two or more hydroxyl or ketohydroxyl groups. The dermatol. disorder treated is one associated with reactive or dilated blood vessels. Also included in the invention are methods of treating dermatol. disorders associated with reactive blood vessels that include topical application of a therapeutically effective amount of a composition

PY 2004
2004
2005

SO U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Formulations and methods for reducing skin irritation

IN Hahn, Gary Scott; Thueson, David Orel

AB Compns. and formulations containing multi-protonated organic polyamines (such as amino acids with amine-containing side groups) and methods of using the same for inhibiting skin irritation in animals, are disclosed. A topical composition containing 7.5 % lactic acid (as skin irritant) and 250 mM spermine·4HCl (as skin anti-irritant) was tested among volunteers to show 52 % inhibition of skin irritation such as burning, itching, erythema.

PY 1996
1996
1996
1997
1998

SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2

=> d his

(FILE 'HOME' ENTERED AT 13:05:27 ON 01 SEP 2006)

FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 13:05:51 ON 01 SEP 2006

L1 2180 S POLYHYDROXY-ALDONIC(W)LACTONE OR GLUCONOLACTONE
L2 107435 S ROSACEA OR DILATED(W)BLOOD(W)VESSELS OR TELANGIECTASIA OR ERY
L3 16903 S ANTI-ACNE(W)AGENT OR ANTI-ACNE(W)MEDIC? OR BENZOYL(W)PEROXIDE
L4 4 S L1 AND L2 AND L3